Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Authorization Holder Scheme To Shake Up China R&D, Production

This article was originally published in PharmAsia News

Executive Summary

China is to introduce on a pilot basis in 10 provinces a new marketing authorization holder scheme, under which a manufacturing site will no longer be required for a drug approval. The change will allow researchers and institutions to hold approvals and is expected to spark changes in both the R&D and contract manufacturing sectors.



Related Companies